Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 |
| Aug 18, 2022 |
| clinicaltrials |
| NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | withdrawn | Phase 1 / Phase 2 | 0 | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | Jan 5, 2022 | clinicaltrials |
| NCT04933669 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors(ZJGIST-01) | recruiting | Phase 2 | 122 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT00028002 | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2020 | clinicaltrials |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | completed | Phase 2 | 34 | Suzanne George, MDOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02015065 | Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02257541 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01440959 | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | completed | Phase 2 | 30 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02889328 | Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00278876 | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation | completed | Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02607332 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03440515 | Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor | completed | Phase 2 | 29 | Asan Medical CenterOTHER | 0 | Jan 7, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02931929 | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT | completed | Phase 1 / Phase 2 | 9 | Medical University InnsbruckOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT00568750 | Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 4 | Jun 17, 2019 | clinicaltrials |
| NCT01396148 | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | completed | Phase 2 | 6 | PfizerINDUSTRY | 3 | Mar 27, 2019 | clinicaltrials |
| NCT02606097 | Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation | completed | Phase 2 | 19 | Chang Gung Memorial HospitalOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01560260 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01874665 | A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor(GIST) | completed | Phase 2 | 45 | Ariad PharmaceuticalsINDUSTRY | 1 | May 18, 2018 | clinicaltrials |
| NCT02336724 | A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor | unknown | Phase 2 | 88 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00867113 | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 91 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00455559 | Ph II Study of Perifosine Plus Gleevec for Patients With GIST | completed | Phase 2 | 40 | AEterna ZentarisINDUSTRY | 0 | Feb 22, 2018 | clinicaltrials |
| NCT02342600 | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | withdrawn | Phase 2 | 0 | Sarcoma Alliance for Research through CollaborationOTHER | 0 | Oct 12, 2017 | clinicaltrials |
| NCT00633295 | Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT03171389 | POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST(POETIG) | unknown | Phase 2 | 81 | Sebastian BauerOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01524848 | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(PAGIST) | completed | Phase 2 | 72 | Scandinavian Sarcoma GroupOTHER | 5 | May 10, 2017 | clinicaltrials |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 2 | 25 | Kristen GanjooOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01089595 | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 2 | 5 | Fox Chase Cancer CenterOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT01110668 | Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00718562 | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00585221 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01483014 | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)(CONVERT) | completed | Phase 2 | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01404650 | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01478373 | Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | completed | Phase 2 | 39 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 27, 2016 | clinicaltrials |
| NCT01039519 | A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 27 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01323400 | Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)(PAZOGIST) | completed | Phase 2 | 81 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00618319 | An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 20 | BiogenINDUSTRY | 1 | Oct 2, 2015 | clinicaltrials |
| NCT02426762 | Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery | unknown | Phase 2 | 100 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00030667 | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 7, 2022source: clinicaltrials